Clinical trials: Anxiety Disorder
Generalized Anxiety Disorder
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
- Trial name
- NCT03829241
- Testing
- Troriluzole
- Where
- 53 sites in United States
- Volunteers
- 881 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Generalized Anxiety Disorder
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD).
- Trial name
- NCT00413010
- Testing
- pregabalin
- Where
- 68 sites in United States, Czechia and 6 more
- Volunteers
- 356 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder
POC Study in Partially Responsive Generalized Anxiety Disorder
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel…
- Trial name
- NCT02310568
- Testing
- PF-06372865.
- Where
- 47 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder
Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects
To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).
- Trial name
- NCT00616655
- Testing
- eszopiclone
- Where
- 57 sites in United States
- Volunteers
- 456 people
- Sponsor
- Sumitomo Pharma America, Inc.
Social Anxiety in Autistic Adults
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.
- Trial name
- NCT02008396
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Resilient Pharmaceuticals
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Growth Hormone Deficiency
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
The purpose of this study is to obtain psychological response and user preference information on the use of the T jet® device versus the traditional subcutaneous injection administration of Tev Tropin®.
- Trial name
- T-jet® (NCT00990340)
- Testing
- T-jet® containing TevTropin®, TevTropin® needle-syringe injection method
- Volunteers
- 52 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Anxiety Disorders
Concentration-QT Study of Paroxetine in Healthy Adults
The primary purpose of the study is to evaluate the potential effect of paroxetine on QTc interval following escalating doses in healthy participants.
- Trial name
- NCT06065735
- Testing
- Paroxetine
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
- Trial name
- VLZ-MD-05 (NCT01629966)
- Testing
- Vilazodone
- Where
- 37 sites in United States
- Volunteers
- 680 people
- Sponsor
- Forest Laboratories
Severe Crohn's Disease, Anxiety
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab
It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.
- Trial name
- RELAX (NCT01428115)
- Where
- 8 sites in Austria
- Volunteers
- 83 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Panic Disorder
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
The purpose of this study is to evaluate the effectiveness of Org 25935 vs. placebo given in combination with cognitive-behavioral therapy (CBT) to reduce the symptoms of panic disorder.
- Trial name
- NCT00725725
- Testing
- Cognitive-behavioral therapy, Org 25935
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Social Anxiety Disorder
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve symptoms of anxiety in adult subjects with social anxiety disorder (SAD) during…
- Trial name
- Palisade-1 (NCT04754802)
- Testing
- PH94B Nasal Spray
- Where
- 21 sites in United States
- Volunteers
- 224 people
- Sponsor
- VistaGen Therapeutics, Inc.
Generalized Anxiety Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
- Trial name
- NCT00744627
- Testing
- Vortioxetine
- Where
- 38 sites in Estonia, Germany and 6 more
- Volunteers
- 301 people
- Sponsor
- Takeda
Anxious Major Depressive Disorder
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
- Trial name
- NCT00759395
- Testing
- AZD2327
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Anxiety Disorders
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.
- Trial name
- NCT00389064
- Testing
- Quetiapine XR
- Where
- 43 sites in United States, Estonia and 3 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Anxiety Neuroses, Anxiety States, Neurotic
A Study in Pediatric Participants With Generalized Anxiety Disorder
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
- Conditions
- Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
- Trial name
- NCT01226511
- Testing
- Duloxetine
- Where
- 24 sites in United States, Mexico and 1 more
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Pain
Evaluation of DEX-IN During Outpatient Procedures
The primary objective of this study is to evaluate the analgesic efficacy of DEX-IN compared with placebo and active control (fentanyl), in subjects undergoing painful outpatient and office based procedures.
- Trial name
- NCT03348423
- Testing
- DEX-IN, Fentanyl
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Baudax Bio
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC